Supplementary material on methods and results
Description
IL-13 is a potent enhancer of neuronal response to different itch stimuli in atopic dermatitis (AD), and Tralokinumab, a fully human IgG4 monoclonal antibody neutralizing IL-13, has demonstrated safety and efficacy in clinical trials and some small real-life studies in treating adult patients with moderate-to-severe AD. We prospectively investigated tralokinumab efficacy and safety in treating adult patients with moderate-to-severe PN-like phenotype AD in a multicenter study during July 2021-November 2022. Our small case series demonstrates the efficacy and safety of tralokinumab in improving PN-like phenotype AD resistant to dupilumab. Given AD as an underlying cause in nearly one-half of PN, our results suggest a potential pathogenic role of the selective blockage of IL-13 with tralokinumab in treating PN.